CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) announced today the completion of its previously announced public offering of 19,000,000 shares of its common stock at a price of $1.75 per share. ARIAD also announced that the underwriters have exercised in full their over-allotment option for the purchase of an additional 2,850,000 shares. Net proceeds of the public offering and the over-allotment option, a total of 21,850,000 shares, are approximately $35.6 million after underwriting discounts and commissions and estimated expenses.
